Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018

  • ID: 4464775
  • Drug Pipelines
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Alligator Bioscience AB
  • Apogenix AG
  • Bristol-Myers Squibb Co
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018

Summary:

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 21 molecules. Out of which approximately 21 molecules are developed by Companies. The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 7 and 6 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Melanoma, Bladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Endometrial Cancer, Follicular Lymphoma, Gastric Cancer, Graft Versus Host Disease (GVHD), Hematological Tumor, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeome Corp
  • Alligator Bioscience AB
  • Apogenix AG
  • Bristol-Myers Squibb Co
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • MORE
Introduction

The Publisher's Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development

Abeome Corp

Alligator Bioscience AB

Apogenix AG

BioInvent International AB

Bristol-Myers Squibb Co

Denceptor Therapeutics Ltd

Enumeral Biomedical Holdings Inc

GigaGen Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Incyte Corp

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Pfizer Inc

Zai Lab Ltd

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles

ATOR-1015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + tavolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENUM-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBR-8383 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3174998 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuOHX-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-1949 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-4083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize OX40L Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04518600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-340 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tavolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tavolimab + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones

Featured News & Press Releases

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015

Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4

Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment

Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Abeome Corp, H1 2018

Pipeline by Alligator Bioscience AB, H1 2018

Pipeline by Apogenix AG, H1 2018

Pipeline by BioInvent International AB, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Denceptor Therapeutics Ltd, H1 2018

Pipeline by Enumeral Biomedical Holdings Inc, H1 2018

Pipeline by GigaGen Inc, H1 2018

Pipeline by GlaxoSmithKline Plc, H1 2018

Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Pipeline by MedImmune LLC, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Zai Lab Ltd, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abeome Corp
  • Alligator Bioscience AB
  • Apogenix AG
  • BioInvent International AB
  • Bristol-Myers Squibb Co
  • Denceptor Therapeutics Ltd
  • Enumeral Biomedical Holdings Inc
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll